share_log

HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18

HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18

HC Wainwright & Co.维持对Astria Therapeutics的买入,将目标价下调至18美元
Benzinga ·  2023/10/12 07:06

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and lowers the price target from $20 to $18.

HC Wainwright&Co.分析师约瑟夫·潘特吉尼斯维持阿斯特里亚治疗公司(纳斯达克:ATXS)的买入,并将目标价从20美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发